Heterogeneous vascular dependence of tumor cell populations
about
Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activationModes of resistance to anti-angiogenic therapyTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Contribution of host-derived tissue factor to tumor neovascularizationAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis.Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanomaMiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy.Angiogenesis, lymphangiogenesis, and melanoma metastasis.Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer.Angiogenesis and melanoma - from basic science to clinical trials.Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.Targeted therapies in oncology: in the crosshairs or at the crossroads?Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells.Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapyAngiogenic inhibitors: a new therapeutic strategy in oncology.High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profileChanges in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Vascular determinants of cancer stem cell dormancy--do age and coagulation system play a role?Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways.Metabolic symbiosis in cancer: refocusing the Warburg lens.Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma.Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.Tumor angiogenesis revisited: Regulators and clinical implications.Modulation of the tumor suppressor protein alpha-catenin by ischemic microenvironment.Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes.Molecular and clinical aspects of targeting the VEGF pathway in tumors.Gd-Hybridized Plasmonic Au-Nanocomposites Enhanced Tumor-Interior Drug Permeability in Multimodal Imaging-Guided Therapy.MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.An insight into tumoral hypoxia: the radiomarkers and clinical applications
P2860
Q24534648-F621F661-03A0-4688-95AF-26960A2C3265Q24608005-9DEC46F4-86E8-43D4-BF8F-37BF36CAA6E4Q30358961-EADADDE0-0DD7-4D8A-A0F1-BCD91E75B5E5Q33765271-3E3363A1-91A5-4C95-9BA5-A56483C03842Q33770680-9D1A680B-9AD3-4B41-99D2-28BEF521A786Q33772197-B1824463-7E00-4955-B757-AF2D584DAF6CQ33778804-90EE0EA2-69C2-457F-BCF2-66D150B1452FQ33931576-325C123E-40DD-416A-B946-744E7354987DQ34203585-BF4EB789-A6A1-47C5-BF19-3BECFF5F8F6DQ34497992-22B64BB6-93F6-4DB6-B1A9-584533877D17Q34981750-258DA622-1711-4897-B463-EB6BE1FFC58CQ35094428-6D40310B-F239-487E-8D5A-E54E852892C4Q35146591-02628A60-77DA-4868-A7C6-86B3DEB74CA9Q35250784-99180426-3383-4D6F-B85C-EBC0863403C9Q35380959-2C0D4ABE-A289-4312-B4AD-A057AA5F7496Q35568530-009B9844-00B9-4A82-9DA9-DC45B9C1F90BQ35641209-77F3A386-848A-480F-97BD-EB1F0B6F1821Q35713698-FEE60338-0C2A-4D45-9006-BD6BDDE4CF33Q35748830-C1E4F910-55CB-4E56-91B2-FAFACA481A58Q36306264-FA24F2A2-90EA-44B3-803D-A3A2C307467FQ36609613-1738D499-F757-43A5-B598-E348E918857FQ37185773-5EC4203C-E204-48DA-AE07-7F49E56E8CEEQ37286259-B4E22B42-0974-4A86-B0BE-B63AB23F0047Q37519522-FED80B55-E20A-48D2-9795-CD5F185D6540Q37974107-B20BEFBF-585B-4986-B8BC-7199666847B5Q38107793-FC14FF3D-8F2D-4D60-ADD6-C75B304C37B1Q38659074-EE9B1A01-56CB-4DBD-A5F2-B8040D326E4DQ39172101-260E5BF6-276A-4BEF-B2A6-D27150372972Q39393740-EA0E723F-C8E3-42B7-97CE-C4D6AC444A94Q39800983-B403E569-B867-4C5F-887B-BEA57E882748Q40020098-97F14FB0-0117-4966-9E4F-DDED45046B14Q40371624-EA9FA602-7C7C-4811-AAB8-585466932419Q42121924-FA347EE6-7B8A-4188-9AFF-D578DA67940AQ48968832-2D0BA6CF-A589-41CE-8499-7B8EE3B3906DQ51061357-9C91DD0F-8D7A-4F31-945A-A36902B7CBE3Q57672097-486FC197-C88D-4CB6-BAAD-E4CF71CED617
P2860
Heterogeneous vascular dependence of tumor cell populations
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Heterogeneous vascular dependence of tumor cell populations
@ast
Heterogeneous vascular dependence of tumor cell populations
@en
type
label
Heterogeneous vascular dependence of tumor cell populations
@ast
Heterogeneous vascular dependence of tumor cell populations
@en
prefLabel
Heterogeneous vascular dependence of tumor cell populations
@ast
Heterogeneous vascular dependence of tumor cell populations
@en
P2093
P2860
P1476
Heterogeneous vascular dependence of tumor cell populations
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)64083-7
P407
P577
2001-04-01T00:00:00Z